BRPI0616223A2 - combinaÇço de fÁrmacos - Google Patents

combinaÇço de fÁrmacos Download PDF

Info

Publication number
BRPI0616223A2
BRPI0616223A2 BRPI0616223-1A BRPI0616223A BRPI0616223A2 BR PI0616223 A2 BRPI0616223 A2 BR PI0616223A2 BR PI0616223 A BRPI0616223 A BR PI0616223A BR PI0616223 A2 BRPI0616223 A2 BR PI0616223A2
Authority
BR
Brazil
Prior art keywords
probucol
combination
tetrazolylalkoxy
prevention
treatment
Prior art date
Application number
BRPI0616223-1A
Other languages
English (en)
Portuguese (pt)
Inventor
Ki Whan Hong
Tomohiro Yoshikawa
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of BRPI0616223A2 publication Critical patent/BRPI0616223A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
BRPI0616223-1A 2005-09-15 2006-09-14 combinaÇço de fÁrmacos BRPI0616223A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US71695405P 2005-09-15 2005-09-15
US60/716,954 2005-09-15
US76177506P 2006-01-25 2006-01-25
US60/761,775 2006-01-25
PCT/JP2006/318675 WO2007032557A1 (en) 2005-09-15 2006-09-14 Combination drug containing probucol and a tetrazolylalkoxy-dihydrocarbostyril derivative with superoxide supressant effects

Publications (1)

Publication Number Publication Date
BRPI0616223A2 true BRPI0616223A2 (pt) 2011-06-14

Family

ID=37420867

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0616223-1A BRPI0616223A2 (pt) 2005-09-15 2006-09-14 combinaÇço de fÁrmacos

Country Status (20)

Country Link
US (2) US8580818B2 (https=)
EP (2) EP1942895B1 (https=)
JP (2) JP5179354B2 (https=)
KR (1) KR101299320B1 (https=)
AR (1) AR057520A1 (https=)
AU (1) AU2006289752B2 (https=)
BR (1) BRPI0616223A2 (https=)
CA (1) CA2620296C (https=)
CY (1) CY1112716T1 (https=)
DK (1) DK1942895T3 (https=)
ES (1) ES2378896T3 (https=)
IL (1) IL189751A0 (https=)
MY (1) MY145787A (https=)
NO (1) NO20081811L (https=)
PL (1) PL1942895T3 (https=)
PT (1) PT1942895E (https=)
RU (1) RU2411945C2 (https=)
SG (1) SG165379A1 (https=)
TW (1) TWI372053B (https=)
WO (1) WO2007032557A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR065588A1 (es) * 2007-03-09 2009-06-17 Otsuka Pharma Co Ltd Un medicamento para tratar enfermedad pulmonar obstructiva cronica
AR070816A1 (es) * 2008-03-14 2010-05-05 Otsuka Pharma Co Ltd Farmaco de combinacion para tratar trastornos vasculares
CN120441542B (zh) * 2025-05-08 2025-09-30 安徽益普克医药科技发展有限公司 一种西洛他唑衍生物及其制备方法与用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5535019A (en) * 1978-09-01 1980-03-11 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
JPH04193836A (ja) 1990-11-26 1992-07-13 Banyu Pharmaceut Co Ltd 抗高脂血症剤
JPH107590A (ja) 1996-06-24 1998-01-13 Chugai Pharmaceut Co Ltd 脳循環障害後遺症または脳虚血後の脳神経障害の治療剤
FR2751540B1 (fr) * 1996-07-26 1998-10-16 Sanofi Sa Composition pharmaceutique antithrombotique
WO1998011896A1 (en) 1996-09-18 1998-03-26 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardiovascular disease
US6245797B1 (en) * 1997-10-22 2001-06-12 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardio-and-cerebrovascular disease
WO1999024400A1 (en) * 1997-11-10 1999-05-20 Vyrex Corporation Probucol esters and uses thereof
US6235311B1 (en) * 1998-03-18 2001-05-22 Bristol-Myers Squibb Company Pharmaceutical composition containing a combination of a statin and aspirin and method
AU5965399A (en) 1998-10-12 2000-05-01 Andreas Bockelmann Pharmaceutically active composition
ATE326240T2 (de) 2000-04-10 2006-06-15 Nicholas John Wald Zusammensetzung zur prävention kardiovaskulärer erkrankungen
US20020115728A1 (en) * 2000-09-05 2002-08-22 Roland Stocker Compositions and methods for treating cardiovascular disorders
PT1385548E (pt) * 2001-01-26 2007-08-24 Schering Corp Combinações de um inibidor ou de inibidores de absorção de esteróis com agente (s) para o tratamento de doenças vasculares
US6576256B2 (en) * 2001-08-28 2003-06-10 The Brigham And Women's Hospital, Inc. Treatment of patients at elevated cardiovascular risk with a combination of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
JP2003192573A (ja) 2001-12-25 2003-07-09 Otsuka Pharmaceut Factory Inc 経口ゲル製剤
TW200301135A (en) * 2001-12-27 2003-07-01 Otsuka Maryland Res Inst Inc Pharmaceutical compositions comprising a multifunctional phosphodiesterase inhibitor and an adenosine uptake inhibitor
US20030181461A1 (en) * 2002-01-25 2003-09-25 Lautt Wilfred Wayne Use of phosphodiesterase antagonists to treat insulin resistance
US6743806B2 (en) * 2002-10-23 2004-06-01 Otsuka Pharmaceutical Company, Limited Active oxygen scavenger
JP2005232059A (ja) 2004-02-18 2005-09-02 Iichiro Shimomura 低アディポネクチン血症予防・治療剤
PT1894576E (pt) 2005-06-08 2011-07-29 Kowa Co Novo agente redutor dos níveis de triglicéridos
JP4193836B2 (ja) 2005-10-24 2008-12-10 ブラザー工業株式会社 インク噴射装置の製造方法

Also Published As

Publication number Publication date
KR20080049822A (ko) 2008-06-04
US8580818B2 (en) 2013-11-12
US20140045889A1 (en) 2014-02-13
AR057520A1 (es) 2007-12-05
JP5179354B2 (ja) 2013-04-10
JP2009508804A (ja) 2009-03-05
AU2006289752B2 (en) 2011-06-09
TWI372053B (en) 2012-09-11
TW200744597A (en) 2007-12-16
EP1942895B1 (en) 2012-02-01
CY1112716T1 (el) 2016-02-10
ES2378896T3 (es) 2012-04-18
NO20081811L (no) 2008-04-14
CA2620296A1 (en) 2007-03-22
JP2013014605A (ja) 2013-01-24
AU2006289752A1 (en) 2007-03-22
WO2007032557A1 (en) 2007-03-22
RU2411945C2 (ru) 2011-02-20
MY145787A (en) 2012-04-30
RU2008114512A (ru) 2009-10-20
IL189751A0 (en) 2008-12-29
DK1942895T3 (da) 2012-03-05
US20090176826A1 (en) 2009-07-09
PL1942895T3 (pl) 2012-07-31
CA2620296C (en) 2013-10-22
EP1942895A1 (en) 2008-07-16
KR101299320B1 (ko) 2013-09-03
SG165379A1 (en) 2010-10-28
HK1122996A1 (en) 2009-06-05
JP5603393B2 (ja) 2014-10-08
EP2275106A1 (en) 2011-01-19
PT1942895E (pt) 2012-03-29

Similar Documents

Publication Publication Date Title
Jo et al. TRPV4 and AQP4 channels synergistically regulate cell volume and calcium homeostasis in retinal Müller glia
Schreml et al. Severe SMA mice show organ impairment that cannot be rescued by therapy with the HDACi JNJ-26481585
AU2018203357B2 (en) New methods
Clausen et al. Mechanisms of rapid reactive oxygen species generation in response to cytosolic Ca2+ or Zn2+ loads in cortical neurons
Amacher Drug-associated mitochondrial toxicity and its detection
Zhan et al. Intravenous anesthetics differentially reduce neurotransmission damage caused by oxygen-glucose deprivation in rat hippocampal slices in correlation with N-methyl-D-aspartate receptor inhibition
Li et al. A novel small-molecule thienoquinolin urea transporter inhibitor acts as a potential diuretic
Fang et al. Mechanisms of star fruit-induced acute renal failure
Stotz et al. Fulminant neuroleptic malignant syndrome after perioperative withdrawal of antiParkinsonian medication
Parodi-Rullán et al. Divergent effects of cyclophilin-D inhibition on the female rat heart: acute versus chronic post-myocardial infarction
Chu et al. β-hydroxybutyrate administered at reperfusion reduces infarct size and preserves cardiac function by improving mitochondrial function through autophagy in male mice
Jaturakan et al. Combination of vitamin E and vitamin C alleviates renal function in hyperoxaluric rats via antioxidant activity
CN110869030A (zh) 用于预防及治疗糖尿病性肾病的包含腺苷衍生物的药学组合物
Meng et al. Effects of chloride channel inhibitors on H2O2-induced renal epithelial cell injury
US20140045889A1 (en) Combination Drug Containing Probucol and a Tetrazolyalkoxy-Dihydrocarbostyril Derivative With Superoxide Supressant Effects
Zhang et al. Activation of autophagy with PF-06409577 alleviates heatstroke-induced organ injury
Ahmet et al. Evaluation of the effect of bupivacaine on the heart tissue in rats with glycerol-induced acute kidney injury
CN101267823B (zh) 具有超氧化物抑制作用的包含普罗布考和四唑基烷氧基-二氢喹诺酮衍生物的组合药物
Rosenkrantz Effects of cannabis on fetal development of rodents
Santos Laso Role of endoplasmic reticulum stress in the pathogenesis of polycystic liver disease: new potential therapeutic target
Falah The role of the cdk5 pathway and NMDA receptor phosphorylation in neurodegeneration in hippocampal sclerosis
Tinson et al. Supporting the intoxicated veterinary patient (part 2): Toxicants affecting the neurological and cardiovascular systems.
Sear Liver dysfunction and the anaesthetist
Lo et al. Articles in PresS. Am J Physiol Endocrinol Metab (September 22, 2015). doi: 10.1152/ajpendo. 00151.2015
Kaye John 0. Bell, Geoffrey Edwards, James L. Maggs, Laurence P. Bishop, Paul M. O'Neill, Stephen A. Ward, Peter A. Winstanley and B. Kevin Park, Department of Pharmacology & Therapeutics, University of Liverpool, Ashton Street, Liverpool L69 3GE.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.